New immunotherapy technology company launched

An immunotherapy technology for treating cancer and other diseases, jointly developed by Victoria University of Wellington’s Ferrier Research Institute and the Malaghan Institute of Medical Research, has been patented and will be the initial focus of a newly-formed company.

Equity investment for the company, called Avalia Immunotherapies, is coming from New Zealand investment firm Powerhouse Ventures, the New Zealand Venture Investment Fund, Malcorp Biodiscoveries Limited and Victoria Link Limited (Victoria University’s commercialisation office). Additional support is also coming from Callaghan Innovation’s technology incubator programme, in the form of a repayable grant, and the Kiwi Innovation Network.

The director of the Ferrier Research Institute, Professor Richard Furneaux, says Avalia Immunotherapies will further develop the ground-breaking technology and aims to progress it to clinical trials.

Read more